GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Itolizumab overview

Itolizumab (T1h, Alzumab / Anti-CD6 ) is a humanized recombinant anti-CD6 monoclonal antibody. It is formulated as injection solution for intravenous infusion. It is indicated for the treatment of patients with active moderate to severe chronic plaque psoriasis who are candidates for systemic therapy. Alzumab is indicated for emergency use in the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19.

Itolizumab is under development for the treatment of systemic lupus erythematosus, acute graft-versus-host disease (aGVHD), lupus nephritis, ulcerative colitis and chronic graft-versus-host disease (cGVHD). It is administered through intravenous and subcutaneous route.

It was also under development for the treatment of Coronavirus disease 2019 (COVID-19), vitiligo, psoriatic arthritis, psoriasis, rheumatoid arthritis, multiple sclerosis, dermatological disorders, refractory lupus nephritis and severe asthma. 

Biocon overview

Biocon is a biopharmaceutical company. It focuses on the research and development of therapies for the treatment of chronic conditions such as cancer, diabetes and autoimmune diseases. It offers a range of active pharmaceutical ingredients (APIs), branded formulations, complex biologics and biosimilars including monoclonal antibodies (MAbs), rh-Insulin, and insulin analogs. The company also provides services including contract manufacturing, drug licensing, research, development, and manufacturing of small and large molecules for biotechnology and pharmaceutical companies across the world. It has a manufacturing facility and R&D center at BioXcell, Malaysia. The company has an operational presence in the UK, Ireland, the US, Switzerland, the UAE, and Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.

For a complete picture of Itolizumab’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.